Evaluating a biomarker for predicting kidney transplant rejection
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation
This study is testing if a specific marker in the blood can help predict kidney transplant rejection in patients so doctors can better tailor their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University Hospital, Angers Government |
| Locations | 1 site (Angers) |
| Trial ID | NCT03994497 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the expression level of CD45RC on T lymphocytes as a potential biomarker for predicting acute rejection in patients undergoing renal transplantation. By analyzing blood samples from participants, the study seeks to identify individuals at higher risk of rejection, thereby allowing for more tailored immunosuppressive strategies. The goal is to improve graft survival rates and patient outcomes following kidney transplants, particularly in those with low immunological risk. This approach addresses a significant gap in current transplant management by focusing on personalized medicine.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 70 who are receiving their first priority renal transplant and have low immunological risk.
Not a fit: Patients who are pregnant, breastfeeding, or those with significant psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved kidney transplant outcomes by enabling personalized immunosuppressive treatment plans.
How similar studies have performed: While the search for predictive biomarkers in transplantation is ongoing, this specific approach using CD45RC is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 and under 70 years old * Patients in care for a first priority renal transplant. * Patients with low immunological risk * Patients with prior written informed consent Exclusion Criteria: * Poor understanding of the French language * Pregnant, breastfeeding or partying women * Persons deprived of liberty by an administrative or judicial decision * Persons undergoing psychiatric care under duress * Adults who are subject to a legal or non-state protection measure to express their consent
Where this trial is running
Angers
- Dr Anne-Sophie GARNIER — Angers, France (Recruiting)
Study contacts
- Study coordinator: Anne-Sophie GARNIER, MD
- Email: AnneSophie.Garnier@chu-angers.fr
- Phone: 0241356075
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.